Professional background
Professor David Barton is the founding director of Neurocentrix. Neurocentrix provides care across three states focusing on treatment-resistant depression, brain injury and early dementia. We have access to depression and early dementia research trials funding through NHMRC and pharmaceutical company funding research. For treatment-resistant depression we offer TMS and esketamine in four sites, Brunswick, Noble Park, Ballarat and Toowong.
David’s subspecialty is in old-age psychiatry, neuropsychiatry (acquired brain injury) and treatment-resistant mood disorder. Professor David Barton has an extensive background in academia with research areas into ketamine, depression and cardiovascular disease funded
Areas of Interest
- Older Persons Mental Health
- Neuropsychiatry
Languages
- English
Telehealth
Yes, upon request
Client groups
- Adults
- Young Adults
- Older Persons
